SOUTH SAN FRANCISCO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that an expanded access protocol (EAP) for Oxbryta® (voxelotor ...

Intends to seek full marketing authorization for Oxbryta to treat hemolytic anemia in sickle cell disease. SOUTH SAN FRANCISCO, Calif., June 24, 2020-- Global Blood Therapeutics, Inc. today ...

“We believe GBT is well positioned for long-term success. As the body of real-world evidence for Oxbryta grows, we initiated multi-center, prospective and retrospective data registries that will ...

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the European Medicines Agency (EMA) has completed the ...

Taken all together, there is a sizable market with strong demand for a highly efficacious and safe drug like Oxbryta. GBT. Figure 4: Near-term catalysts to reach beyond 350K patients.

Positive results from Phase 1 study of GBT601, including incremental new data, support advancing into planned Phase 2/3 trial by mid-year GBT to hold investor conference call and webcast today at ...

SOUTH SAN FRANCISCO, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the Medicines and Healthcare products Regulatory Agency ...

The news came as a shock to Pfizer stock investors following the costly takeover of GBT. Pfizer had estimated Oxbryta and GBT-601 could generate a collective $3 billion in worldwide peak sales.

GBT reported Q4's total net revenues from sales of Oxbryta were $41.3M, which was up by $4.4M or 12% over Q3. For the full year, Oxbryta pulled in roughly $124M despite the ongoing impact of COVID-19.

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that an expanded access protocol (EAP) for Oxbryta® (voxelotor ...

Intends to seek full marketing authorization for Oxbryta to treat hemolytic anemia in sickle cell disease Marketing Authorization Application submission planned by mid-2021 SOUTH SAN FRANCISCO ...

SOUTH SAN FRANCISCO, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the Medicines and Healthcare products Regulatory Agency ...